Behçet Syndrome¶
Chapter 376 | Part 11: Immune-Mediated, Inflammatory, and Rheumatologic Disorders
KEY CLINICAL POINTS¶
- Systemic vasculitis characterized by recurrent oral/genital ulcers, skin lesions, uveitis, and vascular complications
- Diagnosed clinically using International Study Group (ISG) criteria (sensitivity ~95%, specificity ~96%)
- HLA-B51 positivity (50-60% of patients) is a risk factor but not diagnostic
- Neutrophil hyperreactivity and immune dysregulation drive pathogenesis
- Treatment includes corticosteroids, immunosuppressants, and targeted therapies for severe complications
1. DEFINITION & OVERVIEW¶
Behçet syndrome is a systemic vasculitis first described by Hulusi Behçet, characterized by recurrent oral and genital ulcers, skin lesions, uveitis, and multisystem involvement. It is associated with autoinflammatory features but distinct from classical autoinflammatory diseases like familial Mediterranean fever. Disease clusters exist (e.g., acne-like lesions with arthritis/enthesitis), suggesting heterogeneous pathogenesis.
1.1 Clinical Spectrum¶
Manifestations include mucocutaneous ulcers, ocular inflammation, arthritis, vascular lesions (aneurysms, thrombosis), gastrointestinal involvement, and neurologic complications. Symptoms evolve over time with variable combinations.
1.2 Regional Variations¶
Gastrointestinal involvement is rare in Turkey but common in Japan (~30% of US patients). Skin lesions vary by geographic origin.
2. EPIDEMIOLOGY¶
Prevalence peaks in Turkey (1 in 250 adults), Middle East, Mediterranean, and Far East. Most common in late teens to 40s; equal gender distribution but males have more severe disease. HLA-B51 positivity (50-60% of patients) correlates with disease severity but is not diagnostic.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Unknown etiology with genetic predisposition (HLA-B51), innate/adaptive immune activation, and cytokine-driven inflammation. Distinguishes from autoinflammatory diseases via time-dependent remission and absence of autoantibodies/Raynaud’s phenomenon. Neutrophil hyperreactivity may be primary or secondary to cytokine activation.
3.1 Genetic Factors¶
HLA-B51 positivity (50-60% of patients) is a risk factor but not diagnostic. Found in ~20% of healthy populations.
3.2 Immune Mechanisms¶
Involves both innate and adaptive immunity with no association with autoantibodies or serosal involvement. Pathergy reaction (skin hyperreactivity) is a nonspecific marker.
4. CLINICAL FEATURES¶
Oral ulcers (98% prevalence) are the most common presentation. Genital ulcers (80% prevalence) are specific but scarred. Skin lesions include erythema nodosum, acneiform nodules, and superficial thrombophlebitis. Ocular involvement (50% prevalence) includes uveitis. Vascular complications (aneurysms, thrombosis) and CNS manifestations are possible.
4.1 Mucocutaneous Manifestations¶
Oral ulcers: multiple, self-limiting (10-day duration), recurrent unless treated. Genital ulcers: larger, deeper, scarring. Acneiform lesions mimic acne vulgaris but occur at atypical sites.
4.2 Systemic Involvement¶
Gastrointestinal: rare in Turkey, common in Japan. Vascular: superficial thrombophlebitis (linked to DVT), pulmonary artery aneurysms. Neurologic: meningitis, myelitis, stroke.
5. DIFFERENTIAL DIAGNOSIS¶
Acne vulgaris, other vasculitides (e.g., Behçet vs. Crohn’s), Sjögren’s syndrome, and autoimmune diseases. Distinguish by absence of autoantibodies, lack of serosal involvement, and presence of pathergy reaction.
6. INVESTIGATIONS & DIAGNOSIS¶
Clinical diagnosis based on ISG criteria. No specific lab tests, but HLA-B51 may support diagnosis. Workup for vascular complications includes imaging for pulmonary artery aneurysms.
Table 376-1 International Study Group Criteria for the Diagnosis of Behçet Syndrome¶
| CRITERIA | FREQUENCY | COMMENTS |
|---|---|---|
| Oral ulcers | ~98% | At least 3 times in a 12-month period |
| Recurrent genital ulcers | ~80% | Usually scarring |
| Skin lesions | ~80% | Erythema nodosum, pseudofolliculitis, papulopustular or acneiform nodules (postadolescent, not receiving corticosteroids) |
| Eye lesions | ~50% | Anterior or posterior uveitis, cells in vitreous or retinal vasculitis |
| CRITERIA | FREQUENCY | COMMENTS |
|---|---|---|
| Pathergy | ~50% | Evaluated 24–48 h after dermal insertion of a 20-gauge needle |
6.1 Diagnostic Criteria¶
ISG criteria: recurrent oral ulcers + 2 of 4 features (genital ulcers, skin lesions, eye lesions, pathergy). Frequency and comments detailed in Table 376-1.
7. MANAGEMENT & TREATMENT¶
Local care for mucocutaneous lesions. Systemic corticosteroids for acute flares. Immunosuppressants (azathioprine, cyclosporine, TNF inhibitors) for severe disease. Anticoagulation for thrombosis. Surgical intervention for aneurysms. Monitor for CNS complications.
7.1 Pharmacologic Therapy¶
Corticosteroids (oral/IV) for inflammation. Immunosuppressants (azathioprine, cyclosporine, methotrexate). Biologics (TNF- α inhibitors) for refractory cases. Anticoagulants for thrombosis.
7.2 Non-Pharmacologic¶
Oral hygiene to reduce ulcer severity. Avoidance of trauma to trigger pathergy reactions.
8. PROGNOSIS & COMPLICATIONS¶
Variable prognosis with potential for severe complications (aneurysms, CNS involvement, blindness). Mortality <1% but significant morbidity from vascular and neurologic complications.
8.1 Complications¶
Vascular: pulmonary artery aneurysms, deep-vein thrombosis. Neurologic: meningitis, stroke. Ocular: blindness from uveitis.
9. SPECIAL CONSIDERATIONS¶
Pregnancy: no increased risk but monitor for thrombosis. Pediatric cases: milder disease. Elderly: higher risk of vascular complications. Regional variations in GI involvement.
10. KEY POINTS & CLINICAL PEARLS¶
- Diagnose using ISG criteria with oral ulcers + 2 major features. 2. HLA-B51 is a risk factor but not diagnostic. 3. Treat mucocutaneous lesions with local care and systemic steroids. 4. Monitor for vascular complications (aneurysms, thrombosis). 5. Biologics are effective for severe refractory disease.